Relevant bibliographies by topics / Fibrosis regression

Academic literature on the topic 'Fibrosis regression'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fibrosis regression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Fibrosis regression"

1

Landge, Karishma, Vineeta Ojha, KartikP Ganga, Prateek Kaushik, Pooja Sharma, Priya Jagia, Sudheer Arava, et al. "Endomyocardial fibrosis regression." Journal of the Practice of Cardiovascular Sciences 5, no. 2 (2019): 102. http://dx.doi.org/10.4103/jpcs.jpcs_7_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Iredale, John, and Lara Campana. "Regression of Liver Fibrosis." Seminars in Liver Disease 37, no. 01 (February 15, 2017): 001–10. http://dx.doi.org/10.1055/s-0036-1597816.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Andrade, Zilton A. "Schistosomiasis and hepatic fibrosis regression." Acta Tropica 108, no. 2-3 (November 2008): 79–82. http://dx.doi.org/10.1016/j.actatropica.2008.04.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sato, Masaaki, David M. Hwang, Zehong Guan, Jonathan C. Yeung, Masaki Anraku, Dirk Wagnetz, Shin Hirayama, Thomas K. Waddell, Mingyao Liu, and Shaf Keshavjee. "Regression of Allograft Airway Fibrosis." American Journal of Pathology 179, no. 3 (September 2011): 1287–300. http://dx.doi.org/10.1016/j.ajpath.2011.05.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Saffioti, Francesca, and Massimo Pinzani. "Development and Regression of Cirrhosis." Digestive Diseases 34, no. 4 (2016): 374–81. http://dx.doi.org/10.1159/000444550.

Full text
Abstract:
Liver cirrhosis is the ultimate consequence of the wound healing reaction subsequent to a chronic injury, which leads to a complete derangement of the normal hepatic lobular and vascular architecture. Cirrhosis is characterized by patterns of evolution depending on the causative agent and a series of complex underlining mechanisms in which neo-angiogenesis and necro-inflammation play a key role. The importance of the different cell types involved and of the extracellular matrix composition as well as the role of innate immunity, bacterial translocation and oxidative stress are also emerging. A variable degree of regression of fibrosis and even cirrhosis has been described, in experimental models, after suspension of the liver disease causative agent. As some individual features influence the rate of fibrosis progression, genetic and epigenetic factors are likely to influence fibrosis regression. Key Messages: There is increasing awareness that cirrhosis is not a static condition but a dynamic process. Current semi-quantitative scores and clinical classifications are inaccurate and unable to identify the different phases of evolution of the advanced stages of chronic liver diseases (CLDs). The increasing availability of effective etiology-driven therapeutic options for CLDs makes reversion of cirrhosis a more possible prospective. However, the removal of the causing agent, depending on the stage of the disease, does not necessarily eliminate the risk of disease progression, decompensation and development of hepatocellular carcinoma. Also, the non-invasive markers currently validated for the assessment of fibrosis are not suitable for an effective evaluation of fibrosis regression. Conclusions: There is a critical need of a system that would be able to more accurately describe the dynamic development of cirrhosis and the impact of tissue fibrosis, neo-angiogenesis, necro-inflammation and attempted regeneration on its evolution. Effective treatment of CLD can lead to a variable degree of fibrosis regression. New markers able to evaluate this process will need to be detected and validated.
APA, Harvard, Vancouver, ISO, and other styles
6

Caligiuri, Alessandra, Alessandra Gentilini, Mirella Pastore, Stefano Gitto, and Fabio Marra. "Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression." Cells 10, no. 10 (October 15, 2021): 2759. http://dx.doi.org/10.3390/cells10102759.

Full text
Abstract:
Chronic liver injury of different etiologies may result in hepatic fibrosis, a scar formation process consisting in altered deposition of extracellular matrix. Progression of fibrosis can lead to impaired liver architecture and function, resulting in cirrhosis and organ failure. Although fibrosis was previous thought to be an irreversible process, recent evidence convincingly demonstrated resolution of fibrosis in different organs when the cause of injury is removed. In the liver, due to its high regenerative ability, the extent of fibrosis regression and reversion to normal architecture is higher than in other tissues, even in advanced disease. The mechanisms of liver fibrosis resolution can be recapitulated in the following main points: removal of injurious factors causing chronic hepatic damage, elimination, or inactivation of myofibroblasts (through various cell fates, including apoptosis, senescence, and reprogramming), inactivation of inflammatory response and induction of anti-inflammatory/restorative pathways, and degradation of extracellular matrix. In this review, we will discuss the major cellular and molecular mechanisms underlying the regression of fibrosis/cirrhosis and the potential therapeutic approaches aimed at reversing the fibrogenic process.
APA, Harvard, Vancouver, ISO, and other styles
7

Chen, Li, David A. Brenner, and Tatiana Kisseleva. "Combatting Fibrosis: Exosome‐Based Therapies in the Regression of Liver Fibrosis." Hepatology Communications 3, no. 2 (December 13, 2018): 180–92. http://dx.doi.org/10.1002/hep4.1290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Elsharkawy, Aisha, Reham Samir, and Mohamed El-Kassas. "Fibrosis regression following hepatitis C antiviral therapy." World Journal of Hepatology 14, no. 6 (June 27, 2022): 1120–30. http://dx.doi.org/10.4254/wjh.v14.i6.1120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

ZOIS, C. D., G. H. BALTAYIANNIS, P. KARAYIANNIS, and E. V. TSIANOS. "Systematic review: hepatic fibrosis - regression with therapy." Alimentary Pharmacology & Therapeutics 28, no. 10 (November 2008): 1175–87. http://dx.doi.org/10.1111/j.1365-2036.2008.03840.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amital, H. "Fibrosis regression induced by intravenous gammaglobulin treatment." Annals of the Rheumatic Diseases 62, no. 2 (February 1, 2003): 175–77. http://dx.doi.org/10.1136/ard.62.2.175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Fibrosis regression"

1

Fallowfield, Jonathan Andrew. "The role of matrix metalloproteinase-13 in the regression of liver fibrosis." Thesis, University of Southampton, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.443059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bäck, Christer Matthias [Verfasser], Uwe [Akademischer Betreuer] Conrath, and Frank [Akademischer Betreuer] Tacke. "MCP-1 dependent balance of inflammatory pathways and interplay of immune cells in the liver during injury, fibrosis and injury regression : unterschiedliche MCP-1-abhängige Entzündungsmechanismen und Interaktionen von Immunzellen in der Leber / Christer Matthias Bäck ; Uwe Conrath, Frank Tacke." Aachen : Universitätsbibliothek der RWTH Aachen, 2015. http://d-nb.info/1129787419/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fonseca, Yannick de Oliveira. "Cirrose hepática e sua regressão: enfoque na capilarização sinusoidal." s.n, 2011. https://www.arca.fiocruz.br/handle/icict/4149.

Full text
Abstract:
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-06-20T16:52:07Z No. of bitstreams: 1 Yannick de Oliveira Fonseca Cirrose hepática e sua regressão....pdf: 1344580 bytes, checksum: 5f11b790f3db2fcbe68c8d6ae7520132 (MD5)
Made available in DSpace on 2012-06-20T16:52:07Z (GMT). No. of bitstreams: 1 Yannick de Oliveira Fonseca Cirrose hepática e sua regressão....pdf: 1344580 bytes, checksum: 5f11b790f3db2fcbe68c8d6ae7520132 (MD5) Previous issue date: 2011
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil
Os achados morfológicos peculiares da cirrose hepática são representados por suas alterações vasculares, que ocorrem junto com a transformação nodular do parênquima do fígado. Essas alterações são fundamentais para explicar a fisiopatologia da cirrose. Como é sabido, o fígado é o órgão central do metabolismo intermediário; sua circulação interna permite o intercâmbio de macromoléculas que são transformadas e trocadas durante etapas bioquímicas fundamentais em todo o corpo; para tais funções, a existência de sinusóides hepáticos peculiarmente adaptados é crucial. As peculiares alterações vasculares vistas na cirrose hepática têm sido consideradas irreversíveis. O presente estudo se propôs a investigá-Ias em ratos induzidos à cirrose pelo tratamento com tetracloreto de carbono (CCI4) após intervalos de tempo seguintes à sua interrupção. As mudanças estruturais das alterações sinusoidais foram particularmente estudadas por meio de técnicas histológicas, de imunofluorescência para laminina e de microscopia eletrônica de transmissão, quatro a seis meses após a interrupção do CCI4. Durante esse tempo, os nódulos regenerativos tornaram-se progressivamente alargados, enquanto o septos relacionados a eles tornaram-se delicados e fragmentados, especialmente em amostras coletadas seis meses após a interrupção do tratamento. Nossos achados estão de acordo com a sugestão de que, após a interrupção do tratamento durante quatro a seis meses, as mudanças de capilarização sinusoidal vistas na cirrose do rato induzida pelo CCI4 tendem a reverter ao normal com o tempo, apesar da persistência da estrutura nodular do parênquima hepático, as quais estão de acordo com a sugestão de que a cirrose é funcionalmente, embora não morfologicamente, reversível.
Peculiar morphologic findings from hepatic cirrhosis are represented by its vascular changes, which runs along with the nodular transformation of the parenchyma. Such changes are fundamental to explain the physiopathology of cirrhosis. As it is well known, the liver is the central organ of intermediate metabolism. Its internal circulation allows for the exchanges of macromolecules which are transformed and exchanged during fundamental biochemical steps throughout the body; for such functions the existence of peculiarly-adapted fenestrate hepatic sinusoids is crucial. Peculiar vascular alterations seen in hepatic cirrhosis have been considered irreversible. Present study was concerned with investigating vascular changes in carbon tetrachloride (CCI4)-induced cirrhosis in rats after intervals of times following interruption of CCI4 treatment. The structural changes from sinusoidal alterations were particularly studied by means of histological, transmission electron microscopy and immunofluorescent technique for laminin, four to six months following discontinuation of CCI4 treatment. During that time the regenerative nodules were seen to become progressively enlarged while their related septa became delicate and fragmented, especially in samples taken six months after treatment discontinuation. Our findings are in keeping with the suggestion that, following interruption of treatment during four to six months, the changes of sinusoidal capillarization seen in CCl4-induced rat cirrhosis tended to revert to normal with time, in spite of the persistence of the nodular arrangement of the liver parenchyma, wich are in agreement with the suggestion that cirrhosis is functionally, although not morphologically, reversible.
APA, Harvard, Vancouver, ISO, and other styles
4

Trindade, Miguel João Soares. "Elastografia hepática transitória em doentes com hepatite c crónica : influência da terapêutica na regressão da fibrose." Master's thesis, 2015. http://hdl.handle.net/10451/25947.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2015
Introdução: A resposta virológica sustentada tem sido associada a um prognóstico favorável nos doentes com infecção crónica pelo VHC. Os métodos de avaliação da fibrose hepática como a biópsia hepática têm como principal desvantagem serem invasivos. Novos métodos não-invasivos como a elastografia hepática transitória são compatíveis com uma avaliação sequenciada da fibrose hepática e apresentam-se como uma ferramenta valiosa no seguimento destes doentes. Objectivo: Avaliar retrospectivamente a regressão de fibrose hepática e factores associados em doentes com infecção crónica pelo vírus hepatite C, com e sem tratamento antivírico e utilizando elastografia hepática transitória (EHT). Métodos: Foram estudados retrospectivamente doentes com infecção crónica pelo VHC e com pelo menos 2 EHT válidas (Taxa de Sucesso ≥ 60% e IQR/M ≤ 0,3). Os pontos de corte foram definidos através de 110 doentes submetidos a biópsia hepática: 5.43kPa para F≥2 (VPP 0.98; VPN 0.25); 8.18kPa para F≥3 (VPP 0.87 VPN 0.97); 10,08kPa para F=4 (VPP 0.82; VPN 0.98). Os critérios de estratificação utilizados foram os seguintes: sem tratamento (ST) / com tratamento (CT) e com resposta virológica sustentada (RVS) / sem resposta virológica sustentada (SRVS). A regressão de fibrose hepática foi avaliada em todos os doentes com EHT inicial > F2 (>5.43kPa) e definida como a passagem para um estádio inferior de fibrose segundo a classificação de Peter Scheuer. Foi utilizado o Modelo de Regressão de Cox para avaliação dos factores do hospedeiro. Foi considerado como estatisticamente significativo p-value<0.05. Resultados: Foram incluídos 149 doentes, 87 do sexo feminino, idade média 52.5 ± 9.3, distribuída por genótipos (65.7% genótipo 1; 51% 1a) e dividida em dois grupos: ST=57 (38.3%) e CT=92 (61.7%). A RVS foi atingida em 62.9% dos doentes. A mediana dos valores de EHT inicial não foi significativamente diferente entre os grupos CT vs ST (6,45 vs 5,90kPa, p-value 0,236) ou os grupos RVS vs SRVS (6,55 vs 6,35kPa, p-value 0,480). O número médio de EHT foi de 3,3 e o tempo mediano entre a EHT inicial e final foi de 51 meses. O grupo RVS apresentou idade inferior (p-value 0,010), genótipo não 1 mais frequente (p-value 0,001), RNA-VHC inferior (p-value 0,017), γ-GT inferior (p-value<0,001) e contagem de plaquetas superior (p-value 0,049) quando comparado com o grupo SRVS. A regressão foi significativamente superior no grupo RVS: aumento do número de doentes com estádio < F2 (+35,6% p-value 0,001), diminuição do valor médio de EHT (7,1±3,4kPa para 5,0±1,1kPa p-value<0,001), diminuição do valor mediano de EHT (6,55kPa para 5,55kPa p-value<0,001). O grupo RVS apresentou 71% de doentes com regressão vs 26,7% do grupo SRVS (p-value 0,002) e menor tempo mediano até à regressão quando comparado com o da população (38 meses vs 51 meses, p-value 0,045). Foram associados à regressão os seguintes factores: genótipo não 1 (HR 2,478 p-value 0,030), fosfatase alcalina (HR 0,978 p-value 0,040), valor de EHT inicial (HR 0,932 p-value 0,041) e RVS (HR 3,913 p-value 0,010). Conclusões: A regressão de fibrose hepática é um processo lento. A regressão foi mais prevalente e mais rápida no grupo com RVS. A resposta virológica foi o factor que mais influenciou a regressão da fibrose. A EHT permite um follow-up contínuo e fiável ao longo do tempo, característica relevante para avaliar um fenómeno lento como a regressão de fibrose.
Introduction: Sustained virological response has been associated with better prognosis. Former tools to address liver fibrosis were invasive. New non-invasive tools, such as liver stiffness measurements (LSM), are easier to perform sequentially and more valuable in the follow up of chronic hepatitis C patients. Objective: To assess retrospectively fibrosis regression in patients with chronic hepatitis C virus infection with and without antiviral treatment, and its associated factors using LSM. Methods: Patients with chronic HCV infection were retrospectively studied with a minimum of two valid LSM (success rate ≥ 60% and IQR/M ≤ 0.3). The cutoff values were defined by our department in 110 patients submitted to liver biopsy: 5.43kPa for F≥2 (PPV 0.98; NPV 0.25); 8.18kPa for F≥3 (PPV 0.87 NPV 0.97); 10,08kPa for F=4 (PPV 0.82; NPV 0.98). Criteria for stratification were: non treated (NT) / treated (T) and with sustained virological response (SVR) and without (N-SVR) according to the international guidelines definition. Regression of liver fibrosis was defined as transition from higher to a lower stage (Peter Scheuer classification) and was evaluated in all the patients with initial LSM ≥ F2 (5.43 kPa). A Cox Regression Model was used to analyse the regression independent associated factors. Statistical significance p-value <0.05. Results: This study included 149 patients, 87 female, mean age 52.5 ± 9.3, distributed by genotypes (GT) (65.7% GT1; 51% 1a) and divided in two groups: NT=57 (38.3%) and T= 92 (61.7%) patients. The SVR was achieved in 62.9% of the patients. The median pre-treatment LSM were not significantly different between T vs NT (6,45 vs 5,90kPa, p-value 0,236) or SVR vs N-SVR (6,55 vs 6,35kPa, p-value 0,480). The average number of LSM was 3,3 and the median time between first and last LSM was 51 months. The SVR group were younger (p-value 0,010), non 1 genotype was more prevalent (p-value 0,001), had lower viral load (p-value 0,017), lower γ-GT values (p-value<0,001) and higher platelet count (p-value 0,049), when compared against non-SVR. Fibrosis regression was significantly more observed in the SVR group: increase in the number of patients with stage
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Fibrosis regression"

1

Shimizu, Hideharu, Tomasz G. Rogula, and Philip R. Schauer. Safety and Efficacy of Bariatric Surgery in Patients with Cirrhosis. Edited by Tomasz Rogula, Philip Schauer, and Tammy Fouse. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190608347.003.0021.

Full text
Abstract:
Perioperative risks for morbidly obese patients with cirrhosis are significant, and surgeons should consider these risks carefully in deciding on the type of bariatric procedure to be performed. The benefits of bariatric surgery for cirrhotic patients include substantial weight loss, improvements in metabolic diseases, and potential regression of fibrosis, which can also increase their eligibility and candidacy for liver transplantation. There is currently a lack of strong evidence, but the restrictive bariatric procedures are the safest options for carefully selected patients with cirrhosis. Sleeve gastrectomy is likely the best bariatric procedure for obtaining good outcomes without a prohibitive complication rate or mortality for patients with compensated, Child-Pugh class A cirrhosis without portal hypertension. Roux-en-Y gastric bypass is also appropriate for patients who are not suitable for sleeve gastrectomy. Surgeons should be prepared in case they see bariatric patients with cirrhosis diagnosed preoperatively or intraoperatively.
APA, Harvard, Vancouver, ISO, and other styles
2

Zoccali, Carmine, Davide Bolignano, and Francesca Mallamaci. Left ventricular hypertrophy in chronic kidney disease. Edited by David J. Goldsmith. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0107_update_001.

Full text
Abstract:
Alterations in left ventricular (LV) mass and geometry and LV dysfunction increase in prevalence from stage 2 to stage 5 in CKD. Nuclear magnetic resonance is the most accurate and precise technique for measuring LV mass and function in patients with heart disease. Quantitative echocardiography is still the most frequently used means of evaluating abnormalities in LV mass and function in CKD. Anatomically, myocardial hypertrophy can be classified as concentric or eccentric. In concentric hypertrophy, the muscular component of the LV (LV wall) predominates over the cavity component (LV volume). Due to the higher thickness and myocardial fibrosis in patients with concentric LVH, ventricular compliance is reduced and the end-diastolic volume is small and insufficient to maintain cardiac output under varying physiological demands (diastolic dysfunction). In those with eccentric hypertrophy, tensile stress elongates myocardiocytes and increases LV end-diastolic volume. The LV walls are relatively thinner and with reduced ability to contract (systolic dysfunction). LVH prevalence increases stepwisely as renal function deteriorates and 70–80% of patients with kidney failure present with established LVH which is of the concentric type in the majority. Volume overload and severe anaemia are, on the other hand, the major drivers of eccentric LVH. Even though LVH may regress after renal transplantation, the prevalence of LVH after transplantation remains close to that found in dialysis patients and a functioning renal graft should not be seen as a guarantee of LVH regression. The vast majority of studies on cardiomyopathy in CKD are observational in nature and the number of controlled clinical trials in these patients is very small. Beta-blockers (carvedilol) and angiotensin receptors blockers improve LV performance and reduce mortality in kidney failure patients with LV dysfunction. Although current guidelines recommend implantable cardioverter-defibrillators in patients with ejection fraction less than 30%, mild to moderate symptoms of heart failure, and a life expectancy of more than 1 year, these devices are rarely offered to eligible CKD patients. Conversion to nocturnal dialysis and to frequent dialysis schedules produces a marked improvement in LVH in patients on dialysis. More frequent and/or longer dialysis are recommended in dialysis patients with asymptomatic or symptomatic LV disorders if the organizational and financial resources are available.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Fibrosis regression"

1

Arthur, Michael J. P. "Mechanisms of Progression and Regression of Liver Fibrosis." In Liver Cirrhosis, 1–9. Tokyo: Springer Japan, 2001. http://dx.doi.org/10.1007/978-4-431-68343-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vilaseca, Marina, and Jordi Gracia-Sancho. "Drugs to Modify Liver Fibrosis Progression and Regression." In Portal Hypertension VII, 201–18. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08552-9_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pinzani, Massimo. "Liver Fibrosis and Its Regression in the Context of Portal Hypertension." In Portal Hypertension VII, 175–82. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08552-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hernández-Gea, Virginia. "Liver Fibrosis: What Is Reversible and What Not? How to Assess Regression?" In Portal Hypertension VI, 111–15. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23018-4_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weiss, Jeffrey N. "Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFPEF Patients Treated with Allogeneic CDCs." In Stem Cell Surgery Trials in Heart Failure and Diabetes, 21–24. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-78010-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Guido, Maria. "Regression of Liver Fibrosis." In Practical Hepatic Pathology: a Diagnostic Approach, 671–78. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-42873-6.00040-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Arthur, Michael J. P. "Role of Tissue Inhibitors of Metalloproteinases (TIMPs) in the Progression and Regression of Liver Fibrosis." In Extracellular Matrix and the Liver, 347–59. Elsevier, 2003. http://dx.doi.org/10.1016/b978-012525251-5/50020-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bhattacharyya, Swati, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, and John Varga. "Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis." In Prime Archives in Immunology. Vide Leaf, Hyderabad, 2020. http://dx.doi.org/10.37247/pai.1.2020.2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Weitzman, Elissa R., Rosemary E. Ziemnik, Quian Huang, and Sharon Levy. "Alcohol and Marijuana Use and Treatment Nonadherence Among Medically Vulnerable Youth." In Medical Risks of Marijuana, 74–81. American Academy of Pediatrics, 2017. http://dx.doi.org/10.1542/9781610022767-alcohol.

Full text
Abstract:
BACKGROUND AND OBJECTIVE Adolescents face peak risks for onset and intensification of alcohol and marijuana use. However, we know little about these behaviors and their associations with knowledge or treatment adherence among chronically ill youth, a medically vulnerable group. METHODS Cross-sectional assessment of consented youth ages 9 to 18 years receiving care for asthma/cystic fibrosis, type 1 diabetes, arthritis, or inflammatory bowel disease (IBD) by using a self-administered online tool. Prevalence and correlates of risk behaviors and associations with knowledge and treatment adherence were estimated using descriptive statistics and logistic regression, controlling for demographics, mental health, and the multiclinic sampling frame. RESULTS Of 403 consented youth (75.8% response), 51.6% were girls, 75.1% were white, and average age was 15.6 years. Of high school youth, 36.5% and 12.7% reported past-year alcohol use and binge drinking, respectively; 20% reported past-year marijuana use. Among high school youth, 53.1% and 37.2% answered correctly that alcohol can interfere with their medications and laboratory tests; youth answering incorrectly were 8.53 and 4.46 times more likely to drink and binge drink, respectively (P values &lt; .001). Thirty-two percent and 8.3% of high school youth reported regularly forgetting or skipping their medications in the past 30 days; compared with past-year nondrinking youth, drinkers were 1.79 and 1.61 times as likely to report regularly missing or skipping medications (P values &lt; .05). CONCLUSIONS Alcohol and marijuana use are common among youth with chronic medical conditions. Alcohol use is associated with treatment nonadherence. Education and preventive interventions are warranted to ameliorate risk.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Fibrosis regression"

1

Singh, Anuraj, Vaibhav Garg, and Praveen Kumar Sahu. "Scalable Regression Model for Pulmonary Fibrosis." In 2022 IEEE 6th Conference on Information and Communication Technology (CICT). IEEE, 2022. http://dx.doi.org/10.1109/cict56698.2022.9997907.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

J, Prof Madhuri, Vikram Bhushan, Sai Kishore HR, Sharan Kumar G, and Shreyas J. "Prediction of Pulmonary Fibrosis Progression using CNN and Regression." In 2021 3rd International Conference on Advances in Computing, Communication Control and Networking (ICAC3N). IEEE, 2021. http://dx.doi.org/10.1109/icac3n53548.2021.9725730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wohlfahrt, Thomas, Simon Rauber, Markus Luber, Alina Soare, Stefanie Weber, Alexandru-Emil Matei, Chih-Wei Chen, et al. "THU0343 PU.1 INHIBITOR DB1976 CONTROLS FIBROBLAST POLARIZATION IN SYSTEMIC SCLEROSISAND LEADS TO REGRESSION OF FIBROSIS IN DIFFERENT MODELS OF ORGAN FIBROSIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Matsuda, Kenji, Miho Ohsaki, Shigeru Katagiri, Hideto Yokoi, and Katsuhiko Takabayashi. "Application of kernel logistic regression to the prediction of liver fibrosis stages in chronic hepatitis C." In 2012 Joint 6th Intl. Conference on Soft Computing and Intelligent Systems (SCIS) and 13th Intl. Symposium on Advanced Intelligent Systems (ISIS). IEEE, 2012. http://dx.doi.org/10.1109/scis-isis.2012.6505161.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Karpec, D., R. Rudys, L. Leonaviciene, Z. Mackiewicz, R. Bradunaite, G. Kirdaite, R. Rugiene, and A. Venalis. "AB0186 High-dose narrowband ultraviolet a1 induces the regression of dermal fibrosis in animal model of scleroderma." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4262.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pinheiro, Renato Serquiz Elias, Emanuelly da Costa Nobre Soares, Maria Eduarda Bezerra Figueiredo, Stella Mandu Cicco, and Anna Beatriz Graciano Zuza. "Secondary parkinsonism and normal pressure hydrocephaly because of cranioencephalic trauma: a case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.653.

Full text
Abstract:
Context: Normal Pressure Hydrocephalus (NPH) occurs due to the quantitative imbalance of cerebrospinal fluid (CSF), changes in absorption or drainage. It shows idiopathic or secondary etiology. Head trauma (TBI) — which causes brain and/or arachnoid granulations fibrosis and inflammation — impairs CSF reabsorption and induces accumulation in the ventricular system. The diagnosis of sNPH was based on a conjunction of symptoms (e.g.: urinary incontinence, dementia, and gait impairment) and imaging studies. Among the treatments with significant clinical improvement, there are ventriculoperitoneal shunt (VP) and tap test. Case report: FAR, a 74-year old man who was diagnosed with parkinsonian syndrome after 6 months of TBI, showed stiffness, bradykinesia and tremor at rest. In addition, he had CT and Skull MRI. Previous studies suggested PNH. Drug therapy with an optimized dose of Levodopa + Benserazide was established. However, it has shown an unsatisfactory response to antiparkinsonian drugs. Hence, he was submitted to the tap test, obtaining functionality and gait reversion as well as cognitive deficits regression. Those results still remained four weeks after the medical procedure. Conclusions: The work aims to emphasize the importance of a positive tap test response as well as early diagnosis and treatment in the outcome of the morbidity.
APA, Harvard, Vancouver, ISO, and other styles
7

Klisch, Stephen M., and Jeffrey C. Lotz. "Application of a Fiber-Reinforced Continuum Theory to Multiple Deformations of the Annulus Fibrosus." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0118.

Full text
Abstract:
Abstract We applied a fiber-reinforced continuum theory to multiple experimental deformations of annulus fibrosus. Both separate and simultaneous regressions were performed while including the traction-free boundary conditions from tensile experiments.
APA, Harvard, Vancouver, ISO, and other styles
8

Klisch, Stephen M., and Jeffrey C. Lotz. "Application of a Special Theory of Biphasic Mixtures to Annulus Fibrosus." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0127.

Full text
Abstract:
Abstract We applied a special theory of an incompressible mixture of an elastic solid and an inviscid fluid to experimental data (Iatridis et al., 1995) for axial confined compression of annulus fibrosus in finite deformation. We found that this special theory demands a significantly different nonlinear permeability function than the widely used theory of Kwan et al. (1990) and Holmes and Mow (1990) to achieve a best-fit regression to the surface stress time history.
APA, Harvard, Vancouver, ISO, and other styles
9

Groen, Harald C., Thomas T. de Weert, Frank J. H. Gijsen, Anton F. W. van der Steen, Aad van der Lugt, and Jolanda J. Wentzel. "Plaque Ulceration Is Associated With High Stear Stress in Stenotic Carotid Bifurcations." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192614.

Full text
Abstract:
Cerebrovascular events are related to atherosclerotic disease in the carotid arteries and they are often caused by rupture of an atherosclerotic plaque. Rupture-prone, or vulnerable, plaques are characterized by their specific morphology and composition: a large lipid pool covered by a thin fibrous cap infiltrated by macrophages and expansive remodeling. The strength of the cap of a vulnerable plaque is determined by the material properties of the cap and its thickness. Plaque ruptures are often observed at the upstream region of the plaque [1], were the wall shear stress (WSS) is considered to be highest. High WSS is known for its influence on many processes affecting, among others, tissue regression [2]. Therefore, high shear stress induced cap regression might contribute to cap thinning, thus enhancing plaque vulnerability, and eventually leading to cap rupture [3,4]. Here we present the first results of a new approach to study the relationship between WSS and the location of ulcerations in severely stenotic carotid bifurcations by using computational fluid dynamics and computed tomography.
APA, Harvard, Vancouver, ISO, and other styles
10

MAY, DAVID, ELENA SYERKO, TIM SCHMIDT, CHRISTOPHE BINETRUY, LUISA ROCHA DA SILVA, STEPAN LOMOV, and SURESH ADVANI. "BENCHMARKING VIRTUAL PERMEABILITY PREDICTIONS OF REAL FIBROUS MICROSTRUCTURE." In Thirty-sixth Technical Conference. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/asc36/35901.

Full text
Abstract:
ABSTRACT For fast and complete impregnation in Liquid Composite Molding, knowledge about the permeability of the fibrous reinforcement is required. While development of experimental methods continues, a parallel benchmark effort to numerically characterize permeability is being pursued. The approach was to send out the images of a real fibrous microstructure to a number of participants, in order for them to apply their methods for virtual permeability prediction. Via resin transfer molding a plate was manufactured, using the glass woven fabric Hexcel 01102 (295 g/m²) at a fiber volume content of 54% and a thermoset resin. From this plate, a specimen was scanned using a 3D x-ray microscope at a scan size of 1000 x 1000 x 1000 μm³ and a resolution of 0.521 μm³ per voxel. The sample extracted for the simulations with a size of 523 x 65 x 507 μm³ contains about 400 fibers of a single tow. It revealed a variation of filament diameters between 7.5-9.3 μm and a fiber volume content in average of 56.46% with a variation of 54 - 59% in the individual 2D-slices transverse to the fiber direction. The image segmentation was performed by 2D-slices, to which a Hough transform was applied to detect fiber centers and cross-sections. Then fiber paths were tracked through-out the slices by the closest neighbor algorithm. Finally, fiber paths were smoothened by means of the local regression using weighted linear least squares and a 1st degree polynomial model. The participants received a stack of 973 segmented (binary) 2D-images and a corresponding segmented 3D volume raw-file. They were asked to calculate the full permeability tensor components and fill out a detailed questionnaire including questions e.g. on applied flow models and conditions, numerical discretization and approximation methods, fluid properties etc. The received results scatter considerably over two orders of magnitude, although the participants were provided an already segmented image structure, thus eliminating from the beginning a significant source of variation that could have come from image processing. Model size, meshing and many other sources of variation were identified, allowing further specification of the guidelines for the next step.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Fibrosis regression' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography